PNU 159682

Known as: 3'-deamino-3'',4'-anhydro-(2''(S)-methoxy-3''(R)-oxy-4''-morpholinyl)doxorubicin, PNU-159682 
 

Topic mentions per year

Topic mentions per year

2005-2017
01220052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Previous investigations on antibody-drug conjugate (ADC) stability have focused on drug release by linker-deconjugation due to… (More)
Is this relevant?
2017
2017
The DNA alkylating mechanism of PNU-159682 (PNU), a highly potent metabolite of the anthracycline nemorubicin, was investigated… (More)
Is this relevant?
2017
2017
Antibody-drug conjugates (ADC) are highly potent and specific antitumor drugs, combining the specific targeting of mAbs with the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
In most cases, cytotoxic drugs do not preferentially accumulate at the tumor site, causing unwanted toxicities and preventing… (More)
Is this relevant?
2015
2015
PURPOSE We are interested in identifying mechanisms of resistance to the current generation of antibody-drug conjugates (ADC) and… (More)
  • table 1
  • table 2
Is this relevant?
2012
2012
The antitumor anthracycline nemorubicin is converted by human liver microsomes to a major metabolite, PNU-159682 (PNU), which was… (More)
Is this relevant?
2008
2008
We recently demonstrated that nemorubicin (MMDX), an investigational antitumor drug, is converted to an active metabolite, PNU… (More)
Is this relevant?
2005
2005
PURPOSE Nemorubicin (3'-deamino-3'-[2''(S)-methoxy-4''-morpholinyl]doxorubicin; MMDX) is an investigational drug currently in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?